Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 6, Issue 4 (2017)

Regulatory process and ethics for clinical trials in India (CDSCO)

Author(s):
L Evangeline, NVN Mounica, V Sharmila Reddy, MV Ngabhushanam, D Nagarjuna Reddy and Brahmaiah Bonthagarala
Abstract:
India has been a hub for conducting various multi center trials. The Central Drugs Standard Control Organization (CDSCO), headed by the Drug Controller General of India (DCGI), lays down the regulations for the conduct of clinical trials in India. The conduct of trials, regulations in India and quality of data generated may be the cause for this development. It is essential that now all clinical trials conducted in India should as per the International conference of Harmonization-Good Clinical Practices Guidelines (ICH-GCP) for clinical trials and follow the recently amended Schedule Y of the Drugs and Cosmetics Act. Updating our knowledge about these is of utmost importance in today’s turbulent scenario that prevails in the pharmaceutical industry. Thus, this review provides an insight into the recent changes with respect to the regulations of clinical trials and its impact on the clinical research industry in India.
Pages: 165-169  |  1064 Views  36 Downloads
How to cite this article:
L Evangeline, NVN Mounica, V Sharmila Reddy, MV Ngabhushanam, D Nagarjuna Reddy, Brahmaiah Bonthagarala. Regulatory process and ethics for clinical trials in India (CDSCO). Pharma Innovation 2017;6(4):165-169.
The Pharma Innovation Journal